Navigation Links
MannKind Corporation to Hold Second Quarter Financial Results Conference Call on August 11, 2008
Date:8/4/2008

VALENCIA, Calif., Aug. 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2008 second quarter financial results on Monday, August 11, 2008 at 4:00 p.m. EDT.

Management of the Company will host a conference call to discuss the second quarter financial results, clinical progress and other Company developments at 5:00 p.m. EDT on Monday, August 11, 2008. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at http://www.mannkindcorp.com.

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (800) 219-6350 or (402) 220-3904. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere Insulin System, is currently in Phase 3 clinical trials in the United States
'/>"/>

SOURCE MannKind Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. MannKind to Present at the UBS Global Life Sciences Conference
2. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
3. MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation
4. MannKind to Present at the Piper Jaffray Healthcare Conference
5. MannKind to Present at the Wachovia 2008 Healthcare Conference
6. MannKind to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
7. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008
8. MannKind Corporation Response to Recent Market Events
9. Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer
10. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
11. MannKind to Present at the Morgan Stanley Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014  RegeneRx Biopharmaceuticals, Inc. (OTCBB: ... presented at the Fourth International Symposium on Thymosins in ... Italy.  "When thymosin beta 4 (TB4) ... into the peritoneal cavity in a rodent model of ... throughout the brain parenchyma (the functional tissue of the ...
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... The North American crystal oscillator market ... with analysis and forecast of revenue. This market was ... to reach $623.6 million by 2018, at a CAGR ... the TOC of the North American crystal oscillator market ... provided. This also provides a glimpse of the segmentation ...
(Date:10/22/2014)... San Diego, CA (PRWEB) October 22, 2014 ... laboratory balances from Sartorius, A & D Weighing, ... Sartorius CPA Semi-Micro Balance . The Sartorius ... looking for an affordable high-quality, precise, and user-friendly ... in manufacturing of laboratory equipment, their laboratory balances ...
Breaking Biology Technology:Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... groups have stepped forward in an attempt to prevent a ... the state, but outside investors are still in the picture. ... Credential), will meet with four prospective Wisconsin investors on May ... 19 in Green Bay. Those meetings will precede talks with ...
... Wis. - A technology that could enhance the ... avian influenza, and also be useful in vaccine development, ... will receive a Phase II Small Business Innovation Research ... for Allergy & Infectious Diseases. The grant will be ...
... Wis. - The president of the Wisconsin Economic ... to sign a bill that would remove from the books ... investment, but thus far the governor has been non-committal. , ... Legislature, and it has received another boost from James Otterstein, ...
Cached Biology Technology:Wisconsin investors will make their pitch to IPIC 2Pressure mounts for Doyle to repeal shareholder liability law 2
(Date:10/25/2014)... 22, 2014 A recent report, "Genetic Testing ... current and future genetic testing market. A comprehensive introduction ... covered in this report. On account of our analysis ... existing strengths and challenges; forecast for genetic testing has ... to grow at a CAGR of around 9% during ...
(Date:10/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a ... results for its third quarter ended September 30, 2014. ... million, an increase of 40% compared to $4.3 million in ... quarter of 2014 was $4.1 million compared to $1.0 million ... the current three month period was primarily due to: i) ...
(Date:10/17/2014)... Accurate knowledge regarding Ebola is critical and pertinent for ... hazardous global outbreak and epidemic. The Journal, Disaster ... special issue, Ebola Virus and Public Health, to surround ... in this critical societal moment. , On October ... for Clinicians . The primer was prepared by Dr. ...
Breaking Biology News(10 mins):Genetic Testing Market Outlook 2018 2Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7
... study conducted by Dr. Jesus Lovera, Assistant Professor of ... colleagues has found that the herbal supplement Ginkgo biloba ... Sclerosis (MS.) Cognitive impairment affects 40-60% of people with ... executive skills. The research findings were published online ahead ...
... recently awarded $55.5 million to university consortia to ... will advance interdisciplinary nanosystems research and education in ... years, these Nanosystems ERCs, or NERCS, will advance ... issues, such as the human health and environmental ...
... announced continued support of the Colorado BioScience Association ... sciences showcase event in Colorado to be held at ... believe in the goals and community that is fostered by ... CEO of BiOptix.   "As Colorado continues to expand its ...
Cached Biology News:LSUHSC research finds ginkgo biloba doesn’t improve cognitive function in MS 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 2Engineering research centers awarded $55.5 million to innovate in nanoscale science and engineering 3BiOptix Participates in Leading Life Sciences Event BioWest 2012 2
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... innovation from Magnetofection technology, SilenceMag is ... available. Simple, rapid and easy to ... non toxic. Specifically designed for siRNA ... at very low doses of siRNA.,SilenceMag ...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: